other material
confidence high
sentiment neutral
materiality 0.45
Moleculin Biotech sets 1-for-20 reverse split effective Oct 20, 2026; shares outstanding fall to ~1.05M
Moleculin Biotech, Inc.
- Board approved 1-for-20 reverse split after stockholders authorized a ratio of 1-for-2 to 1-for-20 at the Oct 9, 2026 annual meeting.
- Split effective 12:01 a.m. ET Oct 20, 2026; MBRX trades post-split on Nasdaq Capital Market with new CUSIP 60855D507.
- Outstanding shares drop from ~20.91 million to ~1.05 million; authorized shares stay at 500 million; par value unchanged at $0.001.
- No fractional shares issued — holders receive cash equal to the fraction times the 5-day average closing price before the split.
- Restated post-split FY2025 net loss per share $(568.38) vs pre-split $(28.42); net loss $33.56M in FY2025 vs $26.05M in FY2024.